PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
HLB Therapeutics is expanding revenue on its coldchain distribution business while approaching a November topline readout for its global Phase 3 trial (SEER-2) of neurotrophic keratitis candidate RGN-259.
2025 consolidated revenue rose to KRW 69.56bn while the operating loss narrowed to KRW 3.53bn
RGN-259's European Phase 3 trial (SEER-3) again missed statistical significance on its primary endpoint, the fifth such setback
SEER-2, run across 50 sites in the US and Europe, completed its last patient visit, with the company targeting a November topline readout
Owner-attributable net losses widened in both the first and second quarters of 2026
HLB Group Chairman Jin Yang-gon has increased his stake through multiple open-market purchases during 2026
HLB Therapeutics runs two parallel businesses: a biotech R&D arm and a pharmaceutical coldchain distribution business.
The biotech segment centers on RGN-259, an eye disease candidate for dry eye disease and neurotrophic keratitis (NK) developed through US subsidiary ReGenTree, and OKN-007, a recurrent glioblastoma (GBM) candidate developed through another US subsidiary, Oblato.
The coldchain business provides cold-storage and transport services for vaccines and pharmaceuticals, leveraging logistics infrastructure built during COVID-19 vaccine distribution.
In 2025 the company spun off its electronics division into subsidiary Coa Industries, sharpening its focus on the biotech and coldchain businesses. RGN-259 is an eye drop formulation based on Thymosin β4 with corneal wound-healing and anti-inflammatory mechanisms, developed for both dry eye disease and NK indications.
OKN-007 is a nitrone-derivative small molecule expected to improve the tumor microenvironment, and it holds FDA orphan drug designation. Market observers note that the company's current valuation appears centered more on the coldchain business than on the clinical pipeline.
Competitively, limited approved treatment options in NK present an opportunity, but both GBM and NK see parallel global trials from larger pharmaceutical players, meaning commercial success ultimately hinges on final clinical data.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩15.7B | -₩700M | −4.2% |
| 2025Q3 | ₩16.1B | -₩5.4B | −33.5% |
| 2025Q4 | ₩22.8B | ₩4.1B | 18.0% |
| 2026Q1 | ₩13B | -₩3.2B | −24.8% |
| 2026Q2 | ₩12.6B | -₩4.7B | −37.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩48.1B | -₩7.9B | -₩11.4B | −16.4% | −9.7% | 46.5% |
| 2023 | ₩53.7B | -₩8.7B | -₩2.3B | −16.2% | −1.4% | 17.1% |
| 2024 | ₩54.9B | -₩7.6B | -₩22.8B | −13.9% | −14.5% | 20.9% |
| 2025 | ₩69.6B | -₩3.5B | -₩9.2B | −5.1% | −6.1% | 31.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22
Consolidated 2025 revenue reached KRW 69.56bn, up from KRW 54.93bn in 2024, continuing a four-year growth streak from KRW 53.75bn in 2023 and KRW 48.13bn in 2022. The operating loss widened from KRW 7.88bn in 2022 to KRW 8.70bn in 2023, then narrowed to KRW 7.62bn in 2024 and KRW 3.53bn in 2025.
Owner-attributable net loss dropped sharply from KRW 11.35bn in 2022 to KRW 2.30bn in 2023, widened again to KRW 22.79bn in 2024, and narrowed to KRW 9.23bn in 2025.
On a quarterly basis, the third quarter of 2025 saw the operating loss expand to KRW 5.38bn and the owner net loss to KRW 5.28bn, a large loss likely reflecting clinical-related expenses.
By contrast, the fourth quarter of 2025 turned profitable, with revenue of KRW 22.78bn, operating income of KRW 4.09bn, and owner net income of KRW 0.64bn.
However, both the first quarter of 2026 (revenue KRW 13.05bn, operating loss KRW 3.24bn, net loss KRW 4.32bn) and the second quarter (revenue KRW 12.56bn, operating loss KRW 4.73bn, net loss KRW 8.87bn) swung back into losses, with the second-quarter net loss the largest among the trailing five quarters.
Over the trailing four quarters (Q3 2025 through Q2 2026), the cumulative owner net loss reached KRW 17.82bn. The debt ratio also showed volatility in the capital structure, falling from 46.5% in 2022 to 17.1% in 2023 before rising again to 31.5% in 2025.
Neurotrophic keratitis, a rare ophthalmic disease, is considered an area of high unmet medical need given the limited number of currently approved treatments.
At the same time, several candidates including RGN-259 are competing in global clinical development targeting this market, meaning commercialization success hinges on whether final clinical data achieve statistical significance.
Glioblastoma remains a representative unmet-need disease where drug development has stagnated since the introduction of the standard-of-care regimen, which is part of why OKN-007's Phase 2 interim data drew attention from academia and industry.
The coldchain logistics business serves ongoing demand for temperature-controlled distribution of vaccines and biologics, and observers note that a substantial portion of the company's current valuation appears centered on this business.
At the HLB Group level, repeated delays in the US regulatory process for liver cancer drug rivoceranib have weighed on investor sentiment across affiliated companies, and in July 2026 renewed news around HLB's US approval process coincided with a broad decline in group-affiliated stock prices.
While this group-level issue is distinct from HLB Therapeutics' own fundamentals, it remains a variable affecting supply-demand and valuation across the KOSDAQ biotech sector broadly.
With limited formal brokerage coverage, institutional decision-making appears to rely largely on the company's own disclosures and clinical newsflow.
The nearest inflection point is the global Phase 3 trial SEER-2 for RGN-259. Conducted across 50 sites—41 hospitals in the US and 9 across three European countries—the trial has completed its last patient visit and entered the data analysis stage, with the company stating it aims to confirm topline results in November.
Following the earlier European Phase 3 trial SEER-3, which missed statistical significance on its primary endpoint and dampened licensing expectations, the SEER-2 outcome is seen as a key determinant for the entire NK pipeline's trajectory.
In OKN-007's Phase 2 interim data, the 6-month survival rate reached 75.8%, above the 60% target threshold, and a complete response (CR) case was also confirmed, though the specific timing for announcing next-stage development plans has not yet been confirmed.
Given that the coldchain business contributed to the fourth-quarter 2025 swing to quarterly operating profit, whether its revenue growth continues will influence the near-term direction of consolidated earnings.
The company is expected to continue disclosing quarterly results and clinical progress through regular filings, with the SEER-2 outcome and any subsequent partnering discussions likely to be the key items to watch going forward.
HLB Therapeutics does not currently pay dividends, so no dividend-related metrics are established. The price-to-book ratio tends to trade at a level that reflects some premium over net asset value, which can be interpreted as partly incorporating market expectations for the clinical pipeline.
At the same time, some market observers argue that the current valuation is centered more on existing businesses such as coldchain, with pipeline value only partially reflected.
Given that annual results have moved from losses to narrower losses and back to wider losses without a consistent direction, market assessment of earnings stability may continue to shift depending on upcoming clinical outcomes and quarterly performance.
Against this backdrop, tracking relative changes around clinical events may be more informative than viewing the valuation level in absolute terms.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22
The coldchain distribution business posted operating income of KRW 4.09bn in the fourth quarter of 2025, contributing to improved consolidated results. Built on vaccine and biologics distribution infrastructure, this business generates a revenue base independent of clinical trial outcomes.
Given the company's substantial pipeline risk, having a stable source of cash generation serves as a financial buffer.
In interim Phase 2 data for glioblastoma candidate OKN-007, the 6-month survival rate reached 75.8%, well above the 60% target threshold, and a complete response case was also confirmed.
The results drew industry attention as they emerged in a disease area where drug development has stagnated since the standard-of-care regimen was introduced. The candidate has also secured FDA orphan drug designation, providing a supportive regulatory pathway.
With SEER-2 having completed its last patient visit and targeting a November topline readout, a resolution to the long-running clinical uncertainty over RGN-259 is approaching. HLB Group Chairman Jin Yang-gon has increased his stake in HLB Therapeutics through multiple open-market purchases during 2026.
This represents a documented increase in an insider's shareholding, and is a data point that can be monitored alongside market expectations for the clinical outcome.
RGN-259 failed to achieve statistical significance on its primary endpoint in the European Phase 3 trial (SEER-3), the fifth such setback. Given that similar outcomes have recurred across multiple past trials, the possibility that SEER-2 also fails to achieve statistical significance cannot be ruled out. In that scenario, licensing expectations for the NK indication could weaken again.
Owner-attributable net losses widened to KRW 4.32bn and KRW 8.87bn in the first and second quarters of 2026, respectively, compared with prior quarters. This pattern suggests the fourth-quarter 2025 quarterly profit may have reflected temporary factors. The trailing four-quarter cumulative net loss of KRW 17.82bn also raises questions about earnings stability.
HLB Group's liver cancer drug rivoceranib has faced repeated delays in the US approval process due to complete response letters, which has affected share prices across affiliated companies.
Even without a direct link to HLB Therapeutics' own fundamentals, the potential for correlated price swings tied to group-level newsflow remains. The complex governance structure of the HLB Group, which comprises numerous affiliates, is also a variable investors need to continue monitoring.
There is a possibility that RGN-259's SEER-2 trial, like prior trials, fails to achieve statistical significance on its primary endpoint. Similarly, even though OKN-007's Phase 2 interim data were positive, final data or subsequent trials could produce different results.
Both pipelines are run through US subsidiaries, which in some cases limits the scope of domestic disclosure obligations, warranting attention to information accessibility.
HLB Therapeutics is part of the HLB Group, which comprises numerous affiliates, and group-level capital flows or intercompany transactions can affect the assessment of individual companies.
Repeated approval delays for rivoceranib, the group's flagship pipeline, have at times weighed on market confidence across affiliates. Given the large number of affiliated companies, ongoing scrutiny of governance transparency is warranted.
The company has a history of raising development funding through rights offerings and convertible bonds, meaning further capital raises for clinical costs could dilute existing shareholders. The debt ratio has also shown volatility, falling from 46.5% in 2022 to 17.1% in 2023 before rising again to 31.5% in 2025. With annual operating losses persisting, continued monitoring of operating cash flow is warranted.
Check whether the SEER-2 global Phase 3 trial for RGN-259 releases topline results and whether the primary endpoint is met.
Check the third-quarter results for continued coldchain revenue growth and whether the operating loss narrows.
If results are positive, monitor progress in licensing discussions with global pharmaceutical partners; if negative, watch for changes in follow-on pipeline strategy.
Check whether final Phase 2 data for OKN-007 and plans for advancing to Phase 3 are disclosed.
Continue to track disclosures on any further share purchases or sales by Chairman Jin Yang-gon and other major shareholders.
HLB Therapeutics presents a structure where coldchain distribution revenue growth coexists with clinical pipeline uncertainty. Annual revenue grew for a fourth consecutive year in 2025 and the operating loss narrowed, but owner-attributable net losses widened again in the first half of 2026.
The key variable is the topline result of the SEER-2 global Phase 3 trial for RGN-259, expected in November; given five prior related trial failures that have tempered market expectations, the outcome could significantly shift pipeline valuation in either direction.
OKN-007's early clinical data were positive, but next-stage plans have not yet been finalized. As an HLB Group affiliate, the potential for group-level rivoceranib approval issues to spill over into the stock is also worth considering.
With no dividend and limited formal brokerage coverage, investment judgment requires directly tracking disclosures and clinical newsflow.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.